| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 1.22M | 2.2M | 958K | 1.5M | 1.88M |
| Revenue Growth % | - | - | - | - | - | - | 0.81% | -0.56% | 0.57% | 0.25% |
| Cost of Goods Sold | 283K | 387K | 580K | 559K | 344K | 1.85M | 778K | 976K | 1.09M | 1.14M |
| COGS % of Revenue | - | - | - | - | - | 1.53% | 0.35% | 1.02% | 0.73% | 0.61% |
| Gross Profit | -283K | -387K | -580K | -559K | -344K | -639K | 1.42M | -18K | 413K | 740K |
| Gross Margin % | - | - | - | - | - | -0.53% | 0.65% | -0.02% | 0.27% | 0.39% |
| Gross Profit Growth % | - | -0.37% | -0.5% | 0.04% | 0.38% | -0.86% | 3.22% | -1.01% | 23.94% | 0.79% |
| Operating Expenses | 8.72M | 11.14M | 18.85M | 15.2M | 22.24M | 29.07M | 55.15M | 17.98M | 25.55M | 61.78M |
| OpEx % of Revenue | - | - | - | - | - | 23.91% | 25.09% | 18.77% | 17% | 32.84% |
| Selling, General & Admin | 4.19M | 5.46M | 11.68M | 8.69M | 15.45M | 23.28M | 20.39M | 21.53M | 13.29M | 13.79M |
| SG&A % of Revenue | - | - | - | - | - | 19.15% | 9.28% | 22.48% | 8.84% | 7.33% |
| Research & Development | 4.53M | 5.68M | 7.17M | 6.51M | 6.79M | 9.8M | 5.04M | 7.3M | 9.29M | 9.84M |
| R&D % of Revenue | - | - | - | - | - | 8.06% | 2.29% | 7.62% | 6.18% | 5.23% |
| Other Operating Expenses | 2K | 0 | 0 | 91K | 0 | -4.01M | 29.72M | -10.86M | 2.97M | 38.16M |
| Operating Income | -8.72M | -11.14M | -18.85M | -15.2M | -22.24M | -29.71M | -53.73M | -18M | -25.14M | -61.04M |
| Operating Margin % | - | - | - | - | - | -24.43% | -24.44% | -18.79% | -16.72% | -32.45% |
| Operating Income Growth % | -0.75% | -0.28% | -0.69% | 0.19% | -0.46% | -0.34% | -0.81% | 0.67% | -0.4% | -1.43% |
| EBITDA | -8.44M | -10.75M | -18.27M | -14.64M | -21.89M | -29.32M | -49.52M | -12.78M | -23.46M | -59.48M |
| EBITDA Margin % | - | - | - | - | - | -24.11% | -22.53% | -13.34% | -15.61% | -31.62% |
| EBITDA Growth % | -0.8% | -0.27% | -0.7% | 0.2% | -0.5% | -0.34% | -0.69% | 0.74% | -0.84% | -1.54% |
| D&A (Non-Cash Add-back) | 283K | 387K | 580K | 559K | 344K | 394K | 4.21M | 5.22M | 1.68M | 1.56M |
| EBIT | -8.72M | -11.14M | -18.85M | -15.54M | -22.24M | -30.93M | -52.66M | -18.53M | -24.8M | -60.58M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | -252K | -209K | -83K | -52K | -84K |
| Interest Income | 0 | 0 | 0 | 0 | 299K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 19K | 28K | 217K | 216K | 299K | 252K | 209K | 83K | 52K | 84K |
| Other Income/Expense | -17K | -28K | -526K | -552K | -187K | -1.48M | 854K | -615K | 281K | 378K |
| Pretax Income | -8.73M | -11.17M | -19.38M | -15.75M | -22.43M | -31.19M | -52.87M | -18.61M | -24.86M | -60.66M |
| Pretax Margin % | - | - | - | - | - | -25.65% | -24.05% | -19.43% | -16.54% | -32.25% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -1.25M | -9.26M | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 0.96% | 1.21% | 3.92% | 1.12% | 1% |
| Net Income | -8.73M | -11.17M | -19.38M | -15.75M | -22.33M | -29.93M | -64.1M | -72.9M | -27.78M | -60.66M |
| Net Margin % | - | - | - | - | - | -24.62% | -29.16% | -76.1% | -18.48% | -32.25% |
| Net Income Growth % | -0.75% | -0.28% | -0.73% | 0.19% | -0.42% | -0.34% | -1.14% | -0.14% | 0.62% | -1.18% |
| Net Income (Continuing) | -8.73M | -11.17M | -19.38M | -15.75M | -22.43M | -29.93M | -43.61M | -18.61M | -24.86M | -60.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | -20.49M | -54.29M | -2.93M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -8.32 | -8.42 | -12.83 | -8.32 | -8.71 | -9.14 | -14.40 | -20.00 | -3.75 | -4.66 |
| EPS Growth % | -0.82% | -0.01% | -0.52% | 0.35% | -0.05% | -0.05% | -0.58% | -0.39% | 0.81% | -0.24% |
| EPS (Basic) | -8.32 | -8.42 | -12.83 | -8.32 | -8.71 | -9.14 | -14.40 | -20.00 | -3.75 | -4.66 |
| Diluted Shares Outstanding | 1.05M | 1.33M | 1.51M | 1.89M | 2.56M | 3.27M | 4.45M | 5.54M | 7.65M | 13.07M |
| Basic Shares Outstanding | 1.05M | 1.33M | 1.51M | 1.89M | 2.56M | 3.27M | 4.45M | 5.54M | 7.65M | 13.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.93M | 12.7M | 8.53M | 8.64M | 22.96M | 9.23M | 39.14M | 25.54M | 10.7M | 11.76M |
| Cash & Short-Term Investments | 10.54M | 12.41M | 8.36M | 8.46M | 22.45M | 7.82M | 33.85M | 20.43M | 9.43M | 8.64M |
| Cash Only | 8M | 10.17M | 7.6M | 8.03M | 22.07M | 7.14M | 32.95M | 19.99M | 9.43M | 8.64M |
| Short-Term Investments | 2.54M | 2.24M | 760K | 428K | 379K | 675K | 904K | 433K | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 203K | 1.44M | 2.01M | 484K | 1.61M |
| Days Sales Outstanding | - | - | - | - | - | 60.93 | 238.63 | 766.58 | 117.54 | 313 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 304K | 0 | 0 | 410K |
| Days Inventory Outstanding | - | - | - | - | - | - | 142.62 | - | - | 131.16 |
| Other Current Assets | 366K | 285K | 168K | 180K | 425K | 941K | 2.94M | 2.12M | 782K | 1.1M |
| Total Non-Current Assets | 1.81M | 1.75M | 1.69M | 876K | 16.9M | 46.19M | 120.42M | 74.56M | 64.19M | 23.32M |
| Property, Plant & Equipment | 576K | 688K | 822K | 614K | 3.73M | 6.52M | 8.37M | 10.85M | 5.44M | 2.76M |
| Fixed Asset Turnover | - | - | - | - | - | 0.19x | 0.26x | 0.09x | 0.28x | 0.68x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 9.19M | 18.68M | 0 | 0 | 0 |
| Intangible Assets | 1.23M | 988K | 746K | 0 | 0 | 15.01M | 61.72M | 61.63M | 56.59M | 14.61M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 10.96M | 13.42M | 0 | 0 | 0 | 1.7M |
| Other Non-Current Assets | 0 | 75K | 120K | 262K | 2.21M | 1.94M | 31.65M | 2.07M | 2.16M | 4.26M |
| Total Assets | 12.73M | 14.45M | 10.22M | 9.52M | 39.86M | 55.42M | 159.56M | 100.09M | 74.89M | 35.08M |
| Asset Turnover | - | - | - | - | - | 0.02x | 0.01x | 0.01x | 0.02x | 0.05x |
| Asset Growth % | 1% | 0.13% | -0.29% | -0.07% | 3.19% | 0.39% | 1.88% | -0.37% | -0.25% | -0.53% |
| Total Current Liabilities | 2.31M | 4.28M | 4.45M | 5.56M | 4.44M | 9M | 14.12M | 12.11M | 7.19M | 7.28M |
| Accounts Payable | 285K | 422K | 175K | 166K | 469K | 432K | 1.81M | 1.25M | 953K | 2.28M |
| Days Payables Outstanding | 367.58 | 398.01 | 110.13 | 108.39 | 497.63 | 85 | 849.16 | 468.59 | 319.12 | 729.04 |
| Short-Term Debt | 0 | 202K | 1.14M | 1.19M | 1.35M | 2.39M | 1.31M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 847K | 46K | 2.4M | 3.02M | 1.09M | 0 | 6.71M | 4.43M | 4.01M | 2.17M |
| Current Ratio | 4.72x | 2.97x | 1.91x | 1.55x | 5.17x | 1.03x | 2.77x | 2.11x | 1.49x | 1.62x |
| Quick Ratio | 4.72x | 2.97x | 1.91x | 1.55x | 5.17x | 1.03x | 2.75x | 2.11x | 1.49x | 1.56x |
| Cash Conversion Cycle | - | - | - | - | - | - | -467.91 | - | - | -284.89 |
| Total Non-Current Liabilities | 0 | 310K | 1.36M | 534K | 4.58M | 12.94M | 80.23M | 48.39M | 47.23M | 40.08M |
| Long-Term Debt | 0 | 0 | 1.07M | 347K | 1.91M | 1.51M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 310K | 289K | 187K | 2.68M | 4.31M | 3.54M | 2.73M | 2.2M | 2.37M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 7.12M | 76.68M | 45.66M | 45.03M | 37.71M |
| Total Liabilities | 2.31M | 4.58M | 5.81M | 6.09M | 9.02M | 21.94M | 94.35M | 60.5M | 54.42M | 47.35M |
| Total Debt | 0 | 512K | 2.5M | 1.72M | 6.17M | 8.63M | 5.68M | 3.54M | 2.87M | 3.66M |
| Net Debt | -8M | -9.66M | -5.1M | -6.32M | -15.91M | 1.49M | -27.27M | -16.45M | -6.56M | -4.97M |
| Debt / Equity | - | 0.05x | 0.57x | 0.50x | 0.20x | 0.26x | 0.09x | 0.09x | 0.14x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -458.84x | -397.86x | -86.86x | -70.38x | -74.38x | -117.90x | -257.06x | -216.83x | -483.38x | -726.68x |
| Total Equity | 10.42M | 9.86M | 4.4M | 3.42M | 30.84M | 33.48M | 65.22M | 39.59M | 20.47M | -12.27M |
| Equity Growth % | 10.7% | -0.05% | -0.55% | -0.22% | 8.01% | 0.09% | 0.95% | -0.39% | -0.48% | -1.6% |
| Book Value per Share | 9.92 | 7.43 | 2.92 | 1.81 | 12.02 | 10.23 | 14.67 | 7.15 | 2.68 | -0.94 |
| Total Shareholders' Equity | 10.42M | 9.86M | 4.4M | 3.42M | 30.84M | 33.48M | 65.22M | 39.59M | 20.47M | -12.27M |
| Common Stock | 34.9M | 45.82M | 59.97M | 74.74M | 124.58M | 157.16M | 252.95M | 294.93M | 310.3M | 338.24M |
| Retained Earnings | -24.13M | -35.3M | -54.68M | -71.32M | -93.75M | -123.68M | -187.77M | -260.68M | -289.88M | -350.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -350K | -654K | -888K | 0 | 0 | 0 | 37K | 39K | 49K | 21K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.23M | -7.52M | -13.38M | -11.65M | -19.71M | -25.98M | -35.94M | -45.57M | -23.32M | -20.71M |
| Operating CF Margin % | - | - | - | - | - | -21.37% | -16.35% | -47.57% | -15.52% | -11.01% |
| Operating CF Growth % | -2.63% | -0.78% | -0.78% | 0.13% | -0.69% | -0.32% | -0.38% | -0.27% | 0.49% | 0.11% |
| Net Income | -8.73M | -11.17M | -19.38M | -15.75M | -22.43M | -29.93M | -64.1M | -72.9M | -27.78M | -60.66M |
| Depreciation & Amortization | 283K | 387K | 580K | 559K | 351K | 394K | 4.21M | 5.22M | 1.68M | 1.56M |
| Stock-Based Compensation | 1.81M | 922K | 1.63M | 1.48M | 3M | 5.07M | 6.84M | 10.04M | 6.57M | 1.91M |
| Deferred Taxes | 65K | 0 | 4.38M | 956K | 483K | -1.25M | -9.26M | 0 | 0 | 0 |
| Other Non-Cash Items | 18K | 1.7M | 83K | 118K | 437K | -2.24M | 26.22M | 14.01M | 174K | 37.79M |
| Working Capital Changes | 2.33M | 2.34M | -686K | 993K | -1.55M | 1.98M | 149K | -1.94M | -3.97M | -1.32M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -182K | -1.23M | -575K | 109K | -1.13M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -410K |
| Change in Payables | 1.04M | 229K | -48K | 1M | 741K | 848K | -1.35M | 297K | -4.76M | 967K |
| Cash from Investing | 315K | -181K | 843K | -31K | -12.41M | -11.75M | -13.96M | -4.34M | -932K | -512K |
| Capital Expenditures | -500K | -106K | -91K | -31K | -918K | -1.23M | -2.25M | -4.34M | -281K | -516K |
| CapEx % of Revenue | - | - | - | - | - | 1.01% | 1.02% | 4.53% | 0.19% | 0.27% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 815K | -75K | 934K | -240K | -252K | -7K | 0 | 0 | -1.02M | 4K |
| Cash from Financing | 11.65M | 9.88M | 9.97M | 12.11M | 47.87M | 22.8M | 78.36M | 35.81M | 12.19M | 20.43M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | -96K | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 4K | -555K | 8.38M | -201K | 0 | 1.31M | 2.15M | -483K | -427K | -1.79M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -4.73M | -7.63M | -13.48M | -11.68M | -20.63M | -27.21M | -38.19M | -49.91M | -23.61M | -21.23M |
| FCF Margin % | - | - | - | - | - | -22.37% | -17.37% | -52.1% | -15.71% | -11.29% |
| FCF Growth % | -3.03% | -0.61% | -0.77% | 0.13% | -0.77% | -0.32% | -0.4% | -0.31% | 0.53% | 0.1% |
| FCF per Share | -4.50 | -5.75 | -8.93 | -6.17 | -8.04 | -8.31 | -8.59 | -9.01 | -3.09 | -1.62 |
| FCF Conversion (FCF/Net Income) | 0.48x | 0.67x | 0.69x | 0.74x | 0.88x | 0.87x | 0.56x | 0.63x | 0.84x | 0.34x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 209K | 114K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -186.98% | -110.14% | -271.64% | -402.61% | -130.35% | -93.07% | -129.88% | -139.11% | -92.51% | -1480.67% |
| Return on Invested Capital (ROIC) | -187.38% | -637.54% | - | - | -277.06% | -89.3% | -110.52% | -44.19% | -101.77% | - |
| Gross Margin | - | - | - | - | - | -52.55% | 64.6% | -1.88% | 27.48% | 39.34% |
| Net Margin | - | - | - | - | - | -2461.51% | -2916.15% | -7609.81% | -1848.37% | -3225.04% |
| Debt / Equity | - | 0.05x | 0.57x | 0.50x | 0.20x | 0.26x | 0.09x | 0.09x | 0.14x | - |
| Interest Coverage | -458.84x | -397.86x | -86.86x | -70.38x | -74.38x | -117.90x | -257.06x | -216.83x | -483.38x | -726.68x |
| FCF Conversion | 0.48x | 0.67x | 0.69x | 0.74x | 0.88x | 0.87x | 0.56x | 0.63x | 0.84x | 0.34x |
| Revenue Growth | - | - | - | - | - | - | 80.76% | -56.41% | 56.89% | 25.15% |
| 2024 | |
|---|---|
| Pharma Services | 1.86M |
| Pharma Services Growth | - |
| 2024 | |
|---|---|
| UNITED STATES | 1.67M |
| UNITED STATES Growth | - |
| Asia Pacific | 145K |
| Asia Pacific Growth | - |
| GERMANY | 18K |
| GERMANY Growth | - |
Insight Molecular Diagnostics Inc. (IMDX) reported $4.4M in revenue for fiscal year 2024.
Insight Molecular Diagnostics Inc. (IMDX) grew revenue by 25.1% over the past year. This is strong growth.
Insight Molecular Diagnostics Inc. (IMDX) reported a net loss of $60.8M for fiscal year 2024.
Insight Molecular Diagnostics Inc. (IMDX) has a return on equity (ROE) of -1480.7%. Negative ROE indicates the company is unprofitable.
Insight Molecular Diagnostics Inc. (IMDX) had negative free cash flow of $23.9M in fiscal year 2024, likely due to heavy capital investments.